文献速递生殖医学妇科

BRCA突变携带者化疗后卵巢储备损失更严重:卵母细胞DNA双链断裂修复缺陷

Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
PubMed 文献 · Fertil Steril · 2020-04-22

该纵向队列研究纳入108例乳腺癌患者,按BRCA状态分层,比较化疗前后年龄校正的AMH水平。BRCA突变携带者化疗前AMH已降低,化疗后AMH恢复率仅1.6%,显著低于BRCA阴性者和未检测低风险者,提示其卵巢储备损失更严重,应重视生育力保存。

要点

  • BRCA突变携带者化疗前AMH已较对照低24%-34%,提示卵巢衰老加速。
  • 化疗后BRCA突变者AMH恢复率1.6%,显著低于BRCA阴性者3.7%和低风险者5.2%。
  • 建议对BRCA突变女性强调生育力保存,化疗前应评估卵巢储备。

核心结论

  • 携带致病性BRCA突变的女性化疗后卵巢储备损失更严重,应重视生育力保存。
  • DNA修复缺陷可能是衰老、不孕和癌症共享的机制。

研究设计与样本

  • 纵向队列研究,纳入108例可评估的乳腺癌女性。
  • 按BRCA状态分为未检测(阴性家族史,n=35)、BRCA阴性(n=59)和BRCA阳性(n=14)三组。
  • 化疗前及化疗后12-24个月纵向采集血清,检测AMH并按采样时年龄校正。

主要发现

  • 与对照相比,BRCA阴性者和BRCA阳性者化疗前AMH水平分别低24%和34%。
  • 化疗后AMH恢复率:BRCA阳性者1.6%,BRCA阴性者3.7%,未检测/低风险对照5.2%,BRCA阳性者与对照相差三倍。
  • 仅分析最常见方案(多柔比星+环磷酰胺序贯紫杉醇)时结果相似。
  • 体外小鼠卵母细胞BRCA敲低实验显示BRCA缺陷增加卵母细胞对多柔比星的敏感性。

临床怎么用

  • 对携带致病性BRCA突变的乳腺癌女性,化疗前应评估卵巢储备并讨论生育力保存。
  • 化疗后AMH恢复有限,需关注卵巢功能不全风险并为生育咨询提供依据。

局限性

  • BRCA阳性组样本量较小(n=14),结果需更大样本验证。
  • 机制验证仅来自体外小鼠卵母细胞实验,人体机制尚未直接证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether woman who have BRCA mutations (WBM) experience more declines in ovarian reserve after chemotherapy treatment, as it induces oocyte death by deoxyribonucleic acid (DNA) damage, and BRCA mutations result in DNA damage repair deficiency. DESIGN: Longitudinal cohort study. SETTING: Academic centers. PATIENT(S): The 108 evaluable women with breast cancer were stratified into those never tested (negative family history; n = 35) and those negative (n = 59) or positive (n = 14) for a pathogenic BRCA mutation. INTERVENTION(S): Sera were longitudinally obtained before and 12-24 months after chemotherapy treatment, assayed for antimüllerian hormone (AMH), and adjusted for age at sample collection. MAIN OUTCOME MEASURE(S): Ovarian recovery, defined as the geometric mean of the after chemotherapy age-adjusted AMH levels compared with baseline levels. RESULT(S): Compared with the controls, the before chemotherapy treatment AMH levels were 24% and 34% lower in those negative or positive for BRCA mutations, consistent with accelerated ovarian aging in WBM. The WBM had a threefold difference in AMH recovery after chemotherapy treatment (1.6%), when compared with BRCA negative (3.7%) and untested/low risk controls (5.2%). Limiting the analysis to the most common regimen, doxorubicin and cyclophosphamide followed by paclitaxel, showed similar results. These findings were mechanistically confirmed in an in vitro mouse oocyte BRCA knockdown bioassay, which showed that BRCA deficiency results in increased oocyte susceptibility to doxorubicin. CONCLUSION(S): Women who have pathogenic BRCA mutations are more likely to lose ovarian reserve after chemotherapy treatment, suggesting an emphasis on fertility preservation. Furthermore, our findings generate the hypothesis that DNA repair deficiency is a shared mechanism between aging, infertility, and cancer. CLINICAL TRIAL REGISTRATION NUMBER: NCT00823654.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Oktay KH, Bedoschi G, Goldfarb SB, et al. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. Fertil Steril. 2020. PMID: 32331767. doi:10.1016/j.fertnstert.2020.01.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。